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Purpose: The effect of Transcatheter Aortic Valve Implantation (TAVI) on left ventricular (LV) geometry and function
was compared to traditional aortic replacement (AVR) by major surgery.
Methods: 45 patients with aortic stenosis (AS) undergoing TAVI and 33 AVR were assessed by standard echo
Doppler the day before and 2 months after the implantation. 2D echocardiograms were performed to measure left
ventricular (LV) mass index (LVMi), relative wall thickness (RWT), ejection fraction (EF) and the ratio between
transmitral E velocity and early diastolic velocity of mitral annulus (E/e’ ratio). Valvular-arterial impedance (Zva) was
also calculated.
Results: At baseline, the 2 groups were comparable for blood pressure, heart rate, body mass index mean
transvalvular gradient and aortic valve area. TAVI patients were older (p<0.0001) and had greater LVMi (p<0.005)
than AVR group. After 2 months, both the procedures induced a significant reduction of transvalvular gradient and
Zva but the decrease of LVMi and RWT was significant greater after TAVI (both p<0.0001). E/e’ ratio and EF were
significantly improved after both the procedure but E/e’ reduction was greater after TAVI (p<0.0001). TAVI exhibited
greater percent reduction in mean transvalvular gradient (p<0.05), Zva (p<0.02), LVMi (p<0.0001), RWT (p<0.0001)
and E/e’ ratio (p<0.0001) than AVR patients. Reduction of E/e’ ratio was positively related with reduction of RWT
(r = 0.46, p<0.002) only in TAVI group, even after adjusting for age and percent reduction of Zva (r =0.43, p<0.005).
Conclusions: TAVI induces a greater improvement of estimated LV filling pressure in comparison with major
prosthetic surgery, due to more pronounced recovery of LV geometry, independent on age and changes of
hemodynamic load.
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Aortic stenosis (AS) is the most common valvular heart
disease in western countries [1]. It induces pressure
overload of the left ventricle, causing left ventricular
(LV) hypertrophy (LVH) associated with abnormalities of
systolic and diastolic function, recognized risk factors
for cardiac morbidity and mortality [2-6]. The number
of patients with associated co-morbidities and high op-
erative risk is increasing [7]. Transcatheter aortic valve
implantation (TAVI) is a promising therapy for AS in
these high risk patients [8,9]. Several recent studies have
shown feasibility and safety of TAVI in short and mid-
term follow-up periods [10-15]. Survival in patients with
severe AS who cannot undergo surgery has been im-
proved by TAVI [15,16]. The early results are encour-
aging, with reported 30-day mortality rates below 10%
and 1-year survival rates above 70% [15,17-22].
Recent observations have shown how TAVI could be
followed by an immediate decrease in transaortic pres-
sure gradient and a consequent reduction in LV afterload
[23,24]. Although the reduction of LV mass and the im-
provement of LV diastolic function have been demon-
strated to take place early after TAVI [25-28], it is still
unclear whether this recovery is of similar magnitude of
that obtained with open-chest aortic valve replacement
(AVR). Accordingly, the objective of our study was to com-
pare effects of TAVI and traditional AVR on LV geometry
and function using standard Doppler-echocardiography,
over 2-months of follow-up.
Methods
Study population
The study population included consecutive patients with
symptomatic severe AS and high risk [29], who under-
went baseline standard transthoracic echo-Doppler exam
between November 2011 and July 2012 at San Carlo
Hospital (Potenza) and repeated echo Doppler exam 2
months after the respective procedure (TAVI or AVR).
The high risk was established according to the calculated
Society of Thoracic Surgeons (STS) score > 10% [30].
Exclusion criteria included a bicuspid aortic valve dis-
ease (n=1) , previous acute myocardial infarction (n=3),
significant coronary artery disease requiring revasculari-
zation (n=2), LV ejection fraction ≤ 30% (n=5), severe
mitral or aortic valve regurgitation (n=3), atrial fibrilla-
tion (n=3), transient ischemic attack or stroke within the
previous 6 months (n=1), and severe renal insufficiency
(estimated GFR <30 ml/m2).
After exclusions of 18 patients, echo Doppler data of
45 TAVI patients (26 Edwards Sapien XT and 19
Medtronic CoreValve and 33 AVR patients (Carpentier
Edwards SVA) were collected and compared. Written in-
formed consent was obtained from each patient. TAVI
and AVR were performed according to the respectivestandardized procedures [31-33]. Patients undergoing
TAVI were not considered suitable candidates for open-
chest surgery because they had coexisting conditions that
would be associated with a predicted probability of 50% or
more of either death by 30 days after surgery or a serious
irreversible condition [34]. All patients had NHYA class II,
III, or IV symptoms.
Procedures
Standard echocardiographic examination
Doppler echocardiographic exams were performed using
a Vivid 7 ultrasound scanner (GE, USA) equipped with a
2.5 MHz phased-array transducer according to the stan-
dards of our laboratory [35,36]. All echocardiograms
were read off-line by an experienced fellow (ED) at the
Echocardiography Laboratory of Department of Transla-
tional Medical Sciences of the Federico II University
Hospital in Naples, Italy, under the supervision of a se-
nior attending cardiologist (MG). Diagnosis and severity
of aortic valve stenosis was performed by measuring peak
and mean transvalvular aortic gradient and aortic valve
area (AVA) computed by the continuity equation. Aortic
stenosis was defined severe when mean transvalvular gradi-
ent was > 40 mmHg. Standard linear measures were taken
to compute LV mass that was normalized for height
powered to 2.7 (LVMi) [37]. LV hypertrophy (LVH) was
defined as LVMi ≥ 45 g/m2.7 in women and ≥ 49 g/m2.7 in
men. Two-dimensional LV end-diastolic and end-systolic
volumes were measured by the modified Simpson method
(average of apical 4- and 2-chamber views) and ejection
fraction (EF) was calculated. Left atrial (LA) volume was
assessed by the biplane area-length method from the apical
approach, taking care to obtain multiple, dedicated views
of the left atrium purposely oriented to maximize LA area
and optimal definition of LA wall, according to a standard-
ized method [38]. LA volume was indexed for body surface
area (left atrial volume index = LAVi). Stroke volume (ml)
was calculated by pulsed Doppler method of LV outflow
tract and indexed for body surface area (stroke volume
index, ml/m2). Transmitral pulsed Doppler was recorded
in the apical 4-chamber view. Early (E) and atrial (A) peak
velocities (m/sec) and their ratio, and E velocity deceler-
ation time were measured. By pulsed Tissue Doppler, early
diastolic velocity (e’) was measured in apical 4-chamner
view at the lateral mitral annulus. Attention was paid to
the Doppler spectral gain settings and the velocity scale
was kept at about 20 cm/s above and below the baseline.
Minimal angulation (<20°) was maintained between the
ultrasound beam and the plane of cardiac motion during
the sampling of the lateral mitral annular site. The ratio of
transmitral peak E velocity to peak e’ velocity was calcu-
lated as an estimate of LV filling pressure by using e’ vel-
ocity of lateral mitral annulus (E/e’ ratio). Valvular arterial
impedance (Zva) was determined as an index of global LV
Table 1 Characteristics of the 2 study groups at entry
Variables TAVI AVR p
(n=45) (n=33)
Sex (M/F) 25/20 18/15 0.929
Age (years) 80.8 ± 6.2 74.9 ± 4.6 <0.0001
Height (m) 1.63 ± 0.08 1.64 ± 0.05 0.423
Weight (Kg) 66.2 ± 10.3 67.1 ± 9.0 0.694
BSA 1.71 ± 0.16 1.73 ± 0.13 0.554
BMI (kg/m2) 24.8 ± 3,0 24.7 ± 2.3 0.936
Systolic BP (mmHg) 125.6 ± 12.9 129.9 ± 11.3 0.131
Diastolic BP (mmHg) 72.3 ± 9.8 73.7 ± 10.7 0.536
HR (beats/min) 71.9 ± 8.6 73.3 ± 8.1 0.461
STS Score (%) 14.7 ± 3.4 13.8 ± 2.8 0.211
Combined MR (%) 53.3 57.6 0.802
Combined AR (%) 53.3 54.5 0.830
TG max (mmHg) 88.3 ± 14.6 94.1 ± 14.6 0.087
TG mean (mmHg) 48.5 ± 8.8 50.6 ± 7.2 0.255
AVA (cm / m 2) 0.62 ± 0.11 0.61 ± 0.10 0.541
Zva (mmHg/m x m 2) 5.1 ± 1.3 5.5 ± 1.9 0.317
LVMi (g/m 2.7) 80.0 ± 17.9 69.2 ± 15.8 <0.01
RWT 0.56 ± 0.09 0.54 ± 0.08 0.353
EF (%) 52.1 ± 6.9 55.3 ± 8.0 0.063
SVi (ml/m2) 46.8 ± 12.5 43.4 ± 11.9 0.232
E/e’ ratio 11.9 ± 2.9 12.3 ± 2.8 0.537
LAVi (ml/m2) 34.5 ± 7.7 36.2 ± 3.6 0.214
AR = Aortic regurgitation, BSA = Body surface area, BMI = Body mass index, BP =
Blood pressure, E = Transmitral early diastolic velocity, e’ = early diastolic velocity
of mitral annulus , EF = Ejection fraction, HR = Heart rate, HTN = Arterial
hypertension, LAVi = Left atrial volume index, LVMi = Left ventricular mass index,
MR = Mitral regurgitation, RWT = Relative wall thickness, STS = Society of Thoracic
Surgeons, SVi = Stroke volume index, TG = Transvalvular gradient.
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where ΔP = mean transvalvular systolic pressure gradient,
BP = blood pressure and SVI = stroke volume index [39].
Statistical analysis
Statistical analysis was performed by SPSS package, re-
lease 12 (SPSS Inc., Chicago, Illinois, USA). Data are
presented as mean value ± SD. Intergroup comparison
at baseline was obtained by one-factor ANOVA. The
comparison of data before and after surgery (time) and
the impact of the procedure (treatment: TAVI vs. AVR)
was be statistically assessed using a 2-way ANOVA for
repeated measures. Least squares linear regression was
used to evaluate univariate correlates of a given variable.
The null hypothesis was rejected at p ≤ 0.05.
Results
The main clinical characteristics and main echo Doppler
features of the 2 study groups at baseline are reported in
Table 1. The TAVI group was older than the AVR group,
with similar body mass index, blood pressure and heart
rate. TAVI had higher baseline LVMi than AVR, with
comparable transvalvular mean gradient and AVA, Zva,
relative diastolic wall thickness, EF, E/e’ ratio and LAVi.
The prevalence of LVH was 100% (45/45) in the TAVI
group and 91 % (30/33) in the AVR group (data not
reported in Table).
Table 2 shows the comparison of echo Doppler vari-
ables before and after the procedures and impact of the
procedure (TAVI vs. AVR). Both the procedures in-
duced a significant reduction of transvalvular gradient
and Zva but the decrease of LVMi and relative wall
thickness was significantly greater after TAVI. EF was
increased and E/e’ ratio was reduced after either proce-
dures but the E/e’ ratio reduction was significantly
greater after TAVI than after AVR.
Figure 1 displays the comparison of percent changes of
the main echo Doppler parameters between the 2 groups.
Percent reductions of mean transvalvular aortic gradient,
Zva, LVMi, relative wall thickness and E/e’ ratio were sig-
nificantly greater in TAVI than in AVR patients.
Per cent reduction of relative wall thickness was not sig-
nificantly related to either transaortic mean gradient or
Zva in both TAVI (r = 0.22 and r = 0.20, NS) and AVR
group (r = 0.24 and r = 0.23, NS). Similarly, the per cent
reduction of E/e’ ratio was not significantly related with
transaortic mean gradient or Zva in both TAVI (r = 0.10
and r = 0.11, NS) and AVR group (r = 0.13 and r = 0.14,
NS). In contrast, the percent reduction of relative wall
thickness was positively related to the percent reduction of
E/e’ ratio in the TAVI group (r = 0.46, p<0.0002) (Figure 2)
but not in AVR patients (r = 0.04, NS) (Figure 3). The
relation found in the TAVI group remained significant
even after adjusting for age and percent reduction of Zva(r = 0.43, p<0.005). No significant relation was found
between percent reduction of LVMi and percent reduc-
tion of E/e’ ratio in both TAVI (r = 0.18, NS) and AVR
(r = 0.28, NS) groups.
Discussion
The present study demonstrates that 2 months after re-
placement of aortic valve for AS, TAVI induces a faster re-
covery of LV geometry and greater reduction of estimated
LV filling pressure in comparison with traditional AVR and
that the reduced LV filling pressure is strongly due to
changes of the same LV geometry only in TAVI group.
Because of pressure overload, LV structural changes de-
veloping in patients with AS are characterized by LV con-
centric remodeling and concentric LVH. These changes are
associated with myocardial interstitial fibrosis, producing
LV diastolic abnormalities and left atrial remodeling [40]
while systolic chamber dysfunction has a later onset [2-5].
After the substitution of aortic valve, clinical improvement
Table 2 Comparison of echo Doppler variables before and after the procedures and impact of the procedure (TAVI vs. AVR)




HR (beats/m) 71.8 ± 8.6 70.9 ± 7.8 73.3 ± 8.1 73.6 ± 9,3 0.706 0.381
TG max (mmHg) 88.3 ± 14.6 21.3 ± 7.7 94.1 ± 14.6 26.9 ± 5.6 <0.0001 0.950
TG mean (mmHg) 48.5 ± 8.8 11.1 ± 4.2 50.6 ± 7.2 14.0 ± 3.6 <0.0001 0.570
Zva (mmHg/m x m 2) 5.1 ± 1.3 3.9 ± 1.1 5.5 ± 1.9 4.5 ± 1.6 <0.0001 0.225
LVMi (mg/m2.7) 80.0 ± 17.9 70.6 ± 15.7 69.2 ± 15.8 68.7 ± 15.3 <0.0001 <0.0001
RWT 0.56 ± 0.09 0.50 ± 0.08 0.54 ± 0.08 0.54 ± 0.08 <0.0001 <0.0001
EF (%) 52.1 ± 6.9 55.2 ± 8.6 55.3 ± 8.0 57.2 ± 8.8 <0.0001 0.244
SVi (ml/m2) 46.8 ± 12.5 46.6 ± 10.7 43.4 ± 11.9 43.8 ± 10.4 0.886 0.725
E/A ratio 1.06 ± 0.55 1.21 ± 0.32 0.96 ± 0.25 1.10 ± 0.17 <0.001 0.981
E velocity DT (ms) 198.8 ± 76.7 187.4 ± 65.8 194.3 ± 65.7 181.0 ± 50.1 <0.01 <0.815
e’ velocity (cm/s) 8.6 ± 1.3 11.6 ± 1,5 8.9 ± 1.3 12.5 ± 1.6 <0.0001 0.147
E/e’ ratio 11.9 ± 2.9 9.06 ± 1.9 12.3 ± 2.8 11.5 ± 2.2 <0.0001 <0.0001
LAVi (ml/m2) 34.5 ± 7.7 28.2 ± 6.9 36.2 ± 3.6 27.8 ± 3.5 <0.0001 0.484
A = Transmitral atrial velocity, DT = Deceleration time, E = Transmitral early diastolic velocity, e’ = Pulsed Tissue Doppler early diastolic velocity of the lateral mitral
annulus, EF = Ejection fraction, LAVi = Left atrial volume index, LVMi = Left ventricular mass index, RDWT = Relative diastolic wall thickness, SVi = Stroke volume
index, TG = Transvalvular gradient, Zva = Valvular-arterial impedance.
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are observed in late follow-up [4].
Recent studies have demonstrated that TAVI can deter-
mine an early regression of LVH and a significant im-
provement of LV diastolic properties [25-28]. In these
studies the immediate reduction of transvalvular pressureFigure 1 Comparison of per cent reduction of the main echo Dopplergradient was associated with significant reduction of
LV mass [27], improvement of diastolic filling pattern
[25,26,28], reduction of LV filling pressure [27,28] and
decrease in left atrial size [28] while a clear improve-
ment of systolic LV chamber function was observed
only after 3 months [26].parameters in TAVI and AVR groups.
Figure 2 Scatterplot and regression line of the relation between
percent reduction of relative wall thickness and percent reduction
of LV filling pressure in the TAVI group.
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first to document that recovery of LV geometry and im-
provement of LV filling pressure are both more evident
2 months after TAVI than after traditional AVR at the
same time. EF improvement was not significantly differ-
ent between TAVI and AVR group confirming previous
results [26]. However, the reduction of both relative wall
thickness and E/e’ ratio was more pronounced after
TAVI than after AVR while LVMi was significantly reduced
only after TAVI. These findings were further reinforced by
the observation that the percent reductions of relative wall
thickness and E/e’ ratio were substantially greater after
TAVI than after AVR.
It is noteworthy that no relation was detected between
the percent reduction of transvalvular pressure gradient
or Zva and the percent decrease of relative wall thickness
or LV filling pressure in TAVI as well as in AVR group.Figure 3 Scatterplot and regression line of the relation between
percent reduction of relative wall thickness and percent reduction
of LV filling pressure in the AVR group.Accordingly, the substantial difference in the recovery of
LV geometry after TAVI could not be due to the pure re-
duction of loading conditions, but should be ascribed to
own factors related to the respective surgical procedure.
A transient peri-operative LV dysfunction is well rec-
ognized after traditional AVR, this effect being related
to cardiopulmonary by-pass [41]. This transient func-
tional deterioration is further confirmed by elevated BNP
and troponin I serum levels occurring early after AVR
[42,43]. In the TAVI procedure, the consequences of car-
diopulmonary by-pass are avoided and LV remodeling
can occur likely due to less neuro-hormonal stimulus
sustaining initial persistence of LVH.
The main finding of the present study is in fact the rela-
tion between the percent reduction of relative wall thick-
ness and the estimated LV filling pressure (by E/e’ ratio),
found only in the TAVI group. This relation remained sig-
nificant even after adjusting for age and percent reduction
of Zva, an index of LV global load which accounts for the
effects of both AS and systemic arterial compliance, is one
of the main determinant of exercise capacity [44] and is
prognostically validated [42]. In post-cardiac surgery of pa-
tients with overall preserved systolic LV chamber function,
the degree of E/e’ ratio had been shown to be significantly
associated with BNP levels, a finding which indicates left
atrial pressure as a major determinant in BNP release in
this clinical setting [45]. The results of the present study
highlight therefore how the early recovery of LV geometry
occurring after TAVI could be as fast as a beneficial effect
on the reduction of LV filling pressure and may well ex-
plain the evidence of better short and long-term prognosis
of patients with AS undergoing TAVI [18-22]. Elevated LV
filling pressure is the key determinant of cardiac symptoms
and prognosis in patients with chronic heart failure and
coronary artery disease, independent on the values of EF
[46,47]. One-year antihypertensive therapy resulting in
relative wall thickness reduction has been previously found
to be associated with significant improvement of LV dia-
stolic filling parameters related to active relaxation and
passive chamber stiffness, independent of BP reduction, in
hypertensive patients with LVH of the LIFE study [48].
Our results extends these relations to patients with AS
undergoing TAVI in a time period which is substantially
shorter to that needed by anti-hypertensive drugs to
achieve the same effect in arterial systemic hypertension.
Limitations of the study
The main limitation of the study is the short duration
of the follow-up period of TAVI and traditional AVR
patients. While the choice of 2-months period post-
implantation can be judged to be useful in order to
highlight the rapid effectiveness of TAVI in improving
both LV structure and diastolic function, it should also
important to verify whether this improvement could be
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to analyze this aspect.
In conclusion, our study demonstrates that TAVI could
induce a faster recovery of LV geometry than after trad-
itional AVR and the shift from LV concentric remodeling/
hypertrophy could be responsible in its turn of a better
reduction of LV filling pressure, irrespective of changes in
LV afterload.
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